Onderneming Entrada Therapeutics, Inc.
Aandelen
TRDA
US29384C1080
Biotechnologie & Medisch Onderzoek
Beurs gesloten -
Andere beurzen
|
Variatie 5 dagen | Verschil t.o.v. 1 jan (%) | ||
12,15 USD | +2,02% | -6,18% | -19,48% |
Vakgebied
Aantal werknemers: 159
Verkoop per activiteit
USD in miljoen | 2022 | Gewicht | 2023 | Gewicht | Delta |
---|---|---|---|---|---|
Endosomal Escape Vehicle Therapeutics
100,0
%
| 0 | nan % | 129 | 100,0 % | - |
Verkoop per regio
USD in miljoen | 2022 | Gewicht | 2023 | Gewicht | Delta |
---|---|---|---|---|---|
United States
100,0
%
| 0 | nan % | 129 | 100,0 % | - |
Managers
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Dipal Doshi
CEO | Chief Executive Officer | 48 | 01-08-17 |
Kory Wentworth
DFI | Director of Finance/CFO | 45 | 01-11-20 |
Nathan Dowden
PSD | President | 54 | 04-11-19 |
Chief Tech/Sci/R&D Officer | 62 | 01-09-17 | |
Karla MacDonald
PRN | Corporate Officer/Principal | - | 01-06-21 |
Jared Cohen
LAW | General Counsel | - | 01-04-20 |
Kerry Robert
HRO | Human Resources Officer | - | - |
Besturend
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Peter Kim
BRD | Director/Board Member | 65 | 01-12-20 |
Mary Thistle
BRD | Director/Board Member | 64 | 04-05-21 |
Gina Chapman
BRD | Director/Board Member | 57 | 01-09-23 |
Dipal Doshi
CEO | Chief Executive Officer | 48 | 01-08-17 |
Kush Parmar
CHM | Chairman | 42 | 01-10-16 |
Bernhardt Zeiher
BRD | Director/Board Member | 60 | 04-04-23 |
Aandelenklasse
Stemming | Aantal | Vrij verhandelbaar | Bedrijfseigen aandelen | Drijvend Totaal | |
---|---|---|---|---|---|
Aandeel A | 1 | 33 625 578 | 27 644 833 ( 82,21 %) | 24 475 ( 0,0728 %) | 82,21 % |
Bedrijfsgegevens
Sector
Herzieningen van WPA
Vaira. 1 jan. | Kapi. | |
---|---|---|
-19,48% | 394 mln. | |
-3,10% | 102 mld. | |
+2,11% | 96,37 mld. | |
-1,80% | 21,37 mld. | |
-17,75% | 20,92 mld. | |
-6,91% | 18,64 mld. | |
-42,00% | 16,4 mld. | |
-28,19% | 13,53 mld. | |
+0,18% | 13,28 mld. | |
+19,90% | 10,85 mld. |
- Beurs
- Aandelen
- Koers TRDA
- Onderneming Entrada Therapeutics, Inc.